Challenges in biomarker-based clinical trials for patients with gastrointestinal malignancies

References

• Flaherty KT, Le DT, Lemery S. Tissue-agnostic drug development. Am Soc Clin Oncol Educat Book. 2017;37(37):222–230.
   PubMedGoogle Scholar
• Garber K. Tissue-agnostic cancer drug pipeline grows, despite doubts. Nat Rev Drug Discov. 2018;17(4):227–230.
   PubMed Web of Science ®Google Scholar
• Yee LM, Lively TG, McShane LM. Biomarkers in early-phase trials: fundamental issues. Bioanalysis. 2018 Jun 1; 10(12):933–944.
   PubMed Web of Science ®Google Scholar
• Williams PM, Lively TG, Jessup JM, et al. Bridging the gap: moving predictive and prognostic assays from research to clinical use. Clin Cancer Res. 2012 Mar 15;18(6):1531–1539. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307151/
   PubMed Web of Science ®Google Scholar
• Latham A, Srinivasan P, Kemel Y, et al. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol. 2019;37(4):286.
   PubMed Web of Science ®Google Scholar
• Avila M, Meric-Bernstam F. Next-generation sequencing for the general cancer patient. Clin Adv Hematol Oncol. 2019 Aug;17(8):447–454.
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Hovelson DH, Suga JM, et al. Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples. JCO Precis Oncol. 2021;5(5):1312–1324.
   Google Scholar
• Kandel P, Wallace MB. Recent advancement in EUS-guided fine needle sampling. J Gastroenterol. 2019;54(5):377–387.
   PubMed Web of Science ®Google Scholar
• Larson BK, Tuli R, Jamil LH, et al. Utility of endoscopic ultrasound-guided biopsy for next-generation sequencing of pancreatic exocrine malignancies. Pancreas. 2018 Sep;47(8):990–995.
   PubMed Web of Science ®Google Scholar
• Oktay MH, Adler E, Hakima L, et al. The application of molecular diagnostics to stained cytology smears. J Mol Diagn. 2016 May;18(3):407–415.
   PubMed Web of Science ®Google Scholar
• Sheikine Y, Kuo FC, Lindeman NI. Clinical and technical aspects of genomic diagnostics for precision oncology. J Clin Oncol. 2017 Mar 20;35(9):929–933.
   PubMed Web of Science ®Google Scholar
• Woodhouse R, Dennis L, Li M, et al. Clinical and analytical validation of foundationone liquid CDx, a novel 324-gene blood-based comprehensive genomic profiling assay. American Society of Clinical Oncology; 2020Sep 25;15(9):e0237802.
   Google Scholar
• Bruno R, Fontanini G. Next generation sequencing for gene fusion analysis in lung cancer: a literature review. Diagnostics. 2020;10(8):521.
   Web of Science ®Google Scholar
• Solomon J, Benayed R, Hechtman J, et al. Identifying patients with NTRK fusion cancer. Ann Oncol. 2019;30:viii16–viii22.
   Web of Science ®Google Scholar
• Heydt C, Wolwer CB, Velazquez Camacho O, et al. Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation. BMC Med Genomics. 2021 Feb 27;14(1):62.
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Nagy RJ, Braiteh FS, et al. Cell free circulating tumor DNA (ctDNA) landscape in patients with advanced gastroesophageal adenocarcinoma (GEC). J Clin Oncol. 2017;35(4_suppl): 47-47. doi:10.1200/JCO.2017.35.4_suppl.47.
   PubMed Web of Science ®Google Scholar
• Parikh AR, Leshchiner I, Elagina L, et al., Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019;25(9): 1415–1421.
   PubMed Web of Science ®Google Scholar
• Russo M, Siravegna G, Blaszkowsky LS, et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 2016;6(2):147–153.
   PubMed Web of Science ®Google Scholar
• Stahl P, Seeschaaf C, Lebok P, et al. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol. 2015 Feb 5 15(1):7.
   PubMedGoogle Scholar
• Grellety T, Lucchesi C, Hostein I, et al. High-depth sequencing of paired primary and metastatic tumours: implications for personalised medicine. Eur J Cancer. 2017 Oct;84:250–256.
   PubMed Web of Science ®Google Scholar
• Maron SB, Chase LM, Lomnicki S, et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin Cancer Res. 2019 Dec 1 25(23):7098–7112.
   PubMed Web of Science ®Google Scholar
• Nagayama S, Low S-K, Kiyotani K, et al. Precision medicine for colorectal cancer with liquid biopsy and immunotherapy. Cancers (Basel). 2021;13(19):4803.
   PubMed Web of Science ®Google Scholar
• Siravegna G, Mussolin B, Buscarino M, et al., Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7): 795–801.
   PubMed Web of Science ®Google Scholar
• Diaz Jr JLA, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–540.
   PubMed Web of Science ®Google Scholar
• Liu X, George GC, Tsimberidou AM, et al. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015;15(1):713.
   PubMedGoogle Scholar
• Parseghian CM, Loree JM, Morris VK, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2018;30(2):243–249.
   Web of Science ®Google Scholar
• Dasari A, Morris VK, Allegra CJ, et al. ctDNA applications and integration in colorectal cancer: an NCI colon and rectal–anal task forces whitepaper. Nat Rev Clin Oncol. 2020;17(12):757–770.
   PubMed Web of Science ®Google Scholar
• Gupta R, Othman T, Chen C, et al. Guardant360 circulating tumor DNA assay is concordant with FoundationOne next‐generation sequencing in detecting actionable driver mutations in anti‐EGFR naive metastatic colorectal cancer. Oncologist. 2020;25(3):235.
   PubMed Web of Science ®Google Scholar
• Lee JK, Hazar-Rethinam M, Decker B, et al. The pan-tumor landscape of targetable kinase fusions in circulating tumor DNA. Clin Cancer Res. 2022 Feb 15;28(4):728-737.
   Web of Science ®Google Scholar
• Kim Y-W, Kim Y-H, Song Y, et al. Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer. Exp Mol Med. 2019;51(8):1–10.
   Web of Science ®Google Scholar
• Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov. 2020 Jan;19(1):39–56.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Sanchez-Vega F, Jonsson P, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 2018 Jan;8(1):49–58.
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Caporale M, Morano F, et al. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research. Int J Cancer. 2016 Dec 15 139(12):2859–2864.
   PubMed Web of Science ®Google Scholar
• Zhou KI, Peterson B, Serritella A, et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin Cancer Res. 2020 Dec 15 26(24):6453–6463.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Zaidi AH, Smith MA, et al. The dynamic and transient immune microenvironment in locally advanced esophageal adenocarcinoma post chemoradiation. Ann Surg. 2017 Aug 10 266(1):91–98.
   PubMedGoogle Scholar
• Catenacci DV, Tesfaye A, Tejani M, et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019 Jun;15(18):2073–2082.
   PubMed Web of Science ®Google Scholar
• Jain A, Javle M. Molecular profiling of biliary tract cancer: a target rich disease. J Gastrointest Oncol. 2016 Oct;7(5):797–803.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8 362(14):1273–1281.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021 May;22(5):690–701.
   PubMed Web of Science ®Google Scholar
• Bridgewater JA, Goodman KA, Kalyan A, et al. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling. Am Soc Clin Oncol Educ Book. 2016;35(36):e194–203.
   PubMedGoogle Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 Jul 28 357(6349):409–413.
   PubMed Web of Science ®Google Scholar
• Laetsch TW, DuBois SG, Mascarenhas L, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018 May;19(5):705–714.
   PubMed Web of Science ®Google Scholar
• Hong DS, Bauer TM, Lee JJ, et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019 Feb 1 30(2):325–331.
   PubMed Web of Science ®Google Scholar
• Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020 Apr;21(4):531–540.
   PubMed Web of Science ®Google Scholar
• Garber K. Tissue-agnostic cancer drug pipeline grows, despite doubts. Nat Rev Drug Discov. 2018 Apr;17(4):227–229.
   PubMed Web of Science ®Google Scholar
• Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020 Aug 27 383(9):813–824.
   PubMed Web of Science ®Google Scholar
• Chakiba C, Grellety T, Bellera C, et al. Encouraging trends in modern phase 1 oncology trials. N Engl J Med. 2018 Jun 7 378(23):2242–2243.
   PubMed Web of Science ®Google Scholar
• Postel-Vinay S, Aspeslagh S, Lanoy E, et al. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann Oncol. 2016 Feb;27(2):214–224.
   PubMed Web of Science ®Google Scholar
• HMM-J J, Curtis F, Law G, et al. Evaluating follow-up and complexity in cancer clinical trials (EFACCT): an eDelphi study of research professionals’ perspectives. BMJ Open. 2020 Feb 18 10(2):e034269.
   PubMed Web of Science ®Google Scholar
• Malik L, Lu D. Increasing complexity in oncology phase I clinical trials. Invest New Drugs. 2019 Jun;37(3):519–523.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020 Sep;21(9):1234–1243.
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers,version 2.2021,NCCN clinical practice guidelines in oncology. J National Compr Cancer Network. 2021;19(5):541–565.
   PubMedGoogle Scholar
• Silverman IM, Hollebecque A, Friboulet L, et al. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov. 2021;11(2):326–339.
   PubMed Web of Science ®Google Scholar
• Jain A, Borad MJ, Kelley RK, et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precis Oncol. 2018;2(2):1–12.
   PubMedGoogle Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 May;21(5):671–684.
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Moya S, Lomnicki S, et al. Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase II study evaluating an individualized treatment strategy for metastatic disease. Cancer Discov. 2021;11(2):308–325.
   PubMed Web of Science ®Google Scholar
• Unger JM, Cook E, Tai E, et al. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book. 2016;35(36):185–198.
   PubMedGoogle Scholar
• Unger JM, Vaidya R, Hershman DL, et al. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J Natl Cancer Inst. 2019 Mar 1 111(3):245–255.
   PubMedGoogle Scholar
• Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008 Jan 15 112(2):228–242.
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999 Dec 30 341(27):2061–2067.
   PubMed Web of Science ®Google Scholar
• Duma N, Vera Aguilera J, Paludo J, et al. Representation of minorities and women in oncology clinical trials: review of the past 14 years. J Oncol Pract. 2018 Jan;14(1):e1–e10.
   PubMed Web of Science ®Google Scholar
• Ludmir EB, Fuller CD, Moningi S, et al. Sex-based disparities among cancer clinical trial participants. J Natl Cancer Inst. 2020 Feb 1 112(2):211–213.
   PubMedGoogle Scholar
• Kwiatkowski F, Mouret-Reynier MA, Duclos M, et al. Long term improved quality of life by a 2-week group physical and educational intervention shortly after breast cancer chemotherapy completion. Results of the ‘Programme of Accompanying women after breast Cancer treatment completion in Thermal resorts’ (PACThe) randomised clinical trial of 251 patients. Eur J Cancer. 2013 May;49(7):1530–1538.
   PubMed Web of Science ®Google Scholar
• Fayanju OM, Ren Y, Thomas SM, et al. A case-control study examining disparities in clinical trial participation among breast surgical oncology patients. JNCI Cancer Spectr. 2020 Apr;4(2):kz103.
   Web of Science ®Google Scholar
• Kim ES, Atlas J, Ison G, et al. Transforming clinical trial eligibility criteria to reflect practical clinical application. Am Soc Clin Oncol Educ Book. 2016;35(36):83–90.
   PubMedGoogle Scholar
• Rubin EH, Scroggins MJ, Goldberg KB, et al. Strategies to maximize patient participation in clinical trials. Am Soc Clin Oncol Educ Book. 2017;37(37):216–221.
   PubMedGoogle Scholar
• Sohal DPS, Rini BI, Khorana AA, et al. Prospective clinical study of precision oncology in solid tumors. J Natl Cancer Inst. 2015 Nov 9;108(3). doi:10.1093/jnci/djv332.
   PubMedGoogle Scholar
• Kim ES, Bernstein D, Hilsenbeck SG, et al. Modernizing eligibility criteria for molecularly driven trials. J Clin Oncol. 2015 Sep 1 33(25):2815–2820.
   PubMed Web of Science ®Google Scholar
• Gardner B, Doose M, Sanchez JI, et al. Distribution of genomic testing resources by oncology practice and rurality: a nationally representative study. JCO Precis Oncol. 2021;5. doi:10.1200/PO.21.00109.
   PubMed Web of Science ®Google Scholar
• Roberts MC, Spees LP, Freedman AN, et al. Oncologist-reported reasons for not ordering multimarker tumor panels: results from a nationally representative survey. JCO Precis Oncol. 2021;5. doi:10.1200/PO.20.00431.
   Web of Science ®Google Scholar
• Shirdarreh M, Aziza O, Pezo RC, et al. Patients’ and oncologists’ knowledge and expectations regarding tumor multigene next-generation sequencing: a narrative review. Oncologist. 2021 Aug;26(8):e1359–e1371.
   PubMed Web of Science ®Google Scholar
• de Moor JS, Gray SW, Mitchell SA, et al. Oncologist confidence in genomic testing and implications for using multimarker tumor panel tests in practice. JCO Precis Oncol. 2020;4(2020):620–631.
   PubMed Web of Science ®Google Scholar
• Spees LP, Roberts MC, Freedman AN, et al. Involving patients and their families in deciding to use next generation sequencing: results from a nationally representative survey of U.S. oncologists. Patient Educ Couns. 2021 Jan;104(1):33–39.
   PubMed Web of Science ®Google Scholar
• Burkard ME, Deming DA, Parsons BM, et al. Implementation and clinical utility of an integrated academic-community regional molecular tumor board. JCO Precis Oncol. 2017 Jul 5;1:PO.16.00022;1. https://pubmed.ncbi.nlm.nih.gov/32913980/
   PubMed Web of Science ®Google Scholar
• Bruno D, Hess LM, Li X, et al. Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(15_suppl):9005.
   Web of Science ®Google Scholar